Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations

Evaluating the re-identification risk of a clinical study report anonymized under EMA Policy 0070 and Health Canada Regulations

Abstract Background Regulatory agencies, such as the European Medicines Agency and Health Canada, are requiring the public sharing of clinical trial reports that are used to make drug approval decisions. Both agencies have provided guidance for the quantitative anonymization of these clinical report...

Full description

Bibliographic Details
Main Authors: Janice Branson, Nathan Good, Jung-Wei Chen, Will Monge, Christian Probst, Khaled El Emam
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Trials
Online Access:http://link.springer.com/article/10.1186/s13063-020-4120-y

Internet

http://link.springer.com/article/10.1186/s13063-020-4120-y

Similar Items